Complete financial analysis of NervGen Pharma Corp. (NGEN.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NervGen Pharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Chow Tai Fook Jewellery Group Limited (CJEWF) Income Statement Analysis – Financial Results
- Airtel Africa Plc (AAF.L) Income Statement Analysis – Financial Results
- Disruptive Acquisition Corporation I (DISAU) Income Statement Analysis – Financial Results
- Azelis Group NV (AZLGF) Income Statement Analysis – Financial Results
- Cascades Inc. (CADNF) Income Statement Analysis – Financial Results
NervGen Pharma Corp. (NGEN.V)
About NervGen Pharma Corp.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 145.00K | 115.11K | 42.63K | 39.65K | 38.22K | 19.76K | 0.00 |
| Gross Profit | -145.00K | -115.11K | -42.63K | -39.65K | -38.22K | -19.76K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.00M | 16.61M | 6.87M | 6.16M | 6.45M | 780.40K | 0.00 |
| General & Administrative | 9.73M | 6.34M | 5.94M | 5.03M | 3.38M | 578.08K | 11.81K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.73M | 6.34M | 5.94M | 5.03M | 3.38M | 578.08K | 11.81K |
| Other Expenses | 0.00 | 73.37K | 2.05K | 1.43K | 38.22K | 0.00 | 0.00 |
| Operating Expenses | 17.78M | 23.03M | 12.81M | 11.20M | 9.86M | 1.36M | 11.81K |
| Cost & Expenses | 17.78M | 23.03M | 12.81M | 11.20M | 9.86M | 1.36M | 11.81K |
| Interest Income | 550.07K | 201.40K | 29.42K | 18.85K | 98.83K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 514.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 145.00K | 115.11K | 42.63K | 39.65K | 38.22K | 19.76K | 52.52K |
| EBITDA | -17.72M | -20.09M | -12.77M | -11.16M | -9.83M | -1.34M | -11.81K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.78M | -22.82M | -12.87M | -11.19M | -9.86M | -1.36M | -11.81K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.61M | 2.30M | 84.65K | 9.74K | 98.83K | 0.00 | 0.00 |
| Income Before Tax | -22.38M | -20.72M | -12.73M | -11.19M | -9.77M | -1.36M | -11.81K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.62M | -84.65K | -9.74K | -98.83K | -141.38K | -52.52K |
| Net Income | -22.38M | -18.11M | -12.64M | -11.18M | -9.67M | -1.36M | -11.81K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.38 | -0.34 | -0.32 | -0.35 | -0.37 | -0.05 | 0.00 |
| EPS Diluted | -0.38 | -0.34 | -0.32 | -0.35 | -0.37 | -0.05 | 0.00 |
| Weighted Avg Shares Out | 59.29M | 52.65M | 39.29M | 32.11M | 25.90M | 27.20M | 27.20M |
| Weighted Avg Shares Out (Dil) | 59.29M | 52.65M | 39.29M | 32.11M | 25.90M | 27.20M | 27.20M |
Source: https://incomestatements.info
Category: Stock Reports